Claims
- 1. A compound of formula (I): ##STR12## in which Hal is a halogen atom, Alk is a (C.sub.1 -C.sub.4)alkyl group and one of X, and Z is a nitrogen atom and the others are --CH.dbd., and its pharmaceutically acceptable or unacceptable salts.
- 2. A compound of formula (I) according to claim 1 in which Alk is a methyl group and Hal is a chlorine atom, or one of its pharmaceutically acceptable or unacceptable salts.
- 3. A compound as claimed in claim 1 which is 4-Amino-1-(4-chloropyrimidin-2-yl)-4-methylpiperidine and its pharmaceutically acceptable salts.
- 4. A compound as claimed in claim 1 which is 4-Amino-1-(4-chloropyrimidin-2-yl)-4-methylpiperidine maleate.
- 5. A compound as claimed in claim 1 which in 4-Amino-1-(2-chloropyrimidin-4-yl)-4-methylpiperidine and its pharmaceutically acceptable salts.
- 6. A compound as claimed in claim 1 which is 4-Amino-1-(2-chloropyrimidin-4-yl)-4-methylpiperidine maleate.
- 7. A method for inducing a serotoninergic agonist action on 5HT.sub.3 receptors of a mammal which comprises administering to said mammal an effective amount of at least one compound of formula (I): ##STR13## in which Hal is a halogen atom, Alk is a (C.sub.1 -C.sub.4)alkyl group, and one of X, and Z is a nitrogen atom and the others are --CH.dbd., or one of its pharmaceutically acceptable salts.
- 8. A pharmaceutical composition for inducing a serotoninergic agonist action on 5HT.sub.3 receptors of a mammal, wherein the composition contains an effective amount of a compound of formula (I) as claimed in claim 1: ##STR14## in which Hal is a halogen atom, Alk is a (C.sub.1 -C.sub.4)alkyl group and one of X, and Z is a nitrogen atom and the others are --CH.dbd., or one of its pharmaceutically acceptable salts, is present as the active principle.
- 9. A pharmaceutical composition according to claim 8 in which a compound of formula (I) in which Hal is a chlorine atom and Alk is a methyl group, or one of its pharmaceutically acceptable salts, is present as the active principle.
- 10. A pharmaceutical composition in which a compound according to claim 3 is present as the active principle.
- 11. A pharmaceutical composition in which a compound according to claim 5 is present as the active principle.
- 12. A method according to claim 7 for the treatment and/or prophylaxis of dysthymic disorders, psychotic disorders, cases of anxiety or intestinal motivity disorders such as constipation or IBS.
- 13. A method as claimed in claim 7 wherein the compound of formula (I) is 4-amino-1-(4-chloropyrimidin-2-yl)-4-methylpiperidine or a pharmaceutically acceptable salt thereof.
- 14. A method as claimed in claim 7 wherein the compound of formula (I) is 4-amino-1-(4-chloropyrimidin-2-yl)-4-methylpiperidine maleate.
- 15. A method as claimed in claim 7 wherein the compound of formula (I) is 4-amino-1-(2-chloropyrimidin-4-yl)-4-methylpiperidine or a pharmaceutically acceptable salt thereof.
- 16. A method as claimed in claim 7 wherein the compound of formula (I) is 4-amino-1-(2-chloropyrimidin-4-yl)-4-methylpiperidine maleate.
Priority Claims (1)
Number |
Date |
Country |
Kind |
93402498 |
Oct 1993 |
EPX |
|
Parent Case Info
This application is a Division of application Ser. No. 08/319,595, filed Oct. 7, 1994, now U.S. Pat. No. 5,502,063.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4302455 |
Huff et al. |
Nov 1981 |
|
5001125 |
Stokbroekx et al. |
Mar 1991 |
|
Divisions (1)
|
Number |
Date |
Country |
Parent |
319595 |
Oct 1994 |
|